FDA Approved: DOCETAXEL — Supplemental Application (Mylan Institutional LLC)

View source ↗

Summary

FDA approved a supplemental application for docetaxel (docetaxel anhydrous) by Mylan Institutional LLC under ANDA 210072.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)

Snippet

SUPPL AP for DOCETAXEL (DOCETAXEL ANHYDROUS)